a n a ly s i s Cancer sequencing studies have primarily identified cancer driver genes by the accumulation of protein-altering mutations. An improved method would be annotation independent, sensitive to unknown distributions of functions within proteins and inclusive of noncoding drivers. We employed density-based clustering methods in 21 tumor types to detect variably sized significantly mutated regions (SMRs). SMRs reveal recurrent alterations across a spectrum of coding and noncoding elements, including transcription factor binding sites and untranslated regions mutated in up to ~15% of specific tumor types. SMRs demonstrate spatial clustering of alterations in molecular domains and at interfaces, often with associated changes in signaling. Mutation frequencies in SMRs demonstrate that distinct protein regions are differentially mutated across tumor types, as exemplified by a linker region of PIK3CA in which biophysical simulations suggest that mutations affect regulatory interactions. The functional diversity of SMRs underscores both the varied mechanisms of oncogenic misregulation and the advantage of functionally agnostic driver identification.
In cancer, driver mutations alter functional elements of diverse nature and size. For example, melanoma drivers include hyperactivating mutations mapping to single amino acid residues (for example, BRAF Val600; ref. 1), inactivating mutations along tumor-suppressor exons (for example, in PTEN 1 ) and regulatory mutations (for example, in the TERT promoter 2 ). Cancer genomics projects such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) have substantially expanded our understanding of the landscape of somatic alterations by identifying frequently mutated protein-coding genes [3] [4] [5] . However, these studies have focused little attention on systematically analyzing the positional distribution of coding mutations or characterizing noncoding alterations 6 . Algorithms to identify cancer driver genes often examine nonsynonymous-to-synonymous mutation rates across the gene body or recurrently mutated amino acids called mutation hotspots 5 , as observed in BRAF 7 , IDH1 (ref. 8) and DNA polymerase ε (encoded by POLE) 9 . Yet, these analyses ignore recurrent alterations in the vast intermediate scale of functional coding elements, such as those affecting protein subunits or interfaces. Moreover, where mutation clustering within genes has been examined [10] [11] [12] , analyses have employed windows of fixed length or identified clusters of nonsynonymous mutations, assuming that driver mutations exclusively influence protein sequence and ignoring the importance of exonembedded regulatory elements [13] [14] [15] [16] [17] [18] .
A significant proportion of regulatory elements in the genome are located proximal to or even in exons 15, 19 , suggesting that many may be captured by whole-exome sequencing. Efforts to characterize noncoding regulatory variation in cancer genomes have primarily examined either (i) pan-cancer whole-genome sequencing data or (ii) predefined regions-such as ETS-binding sites, splicing signals, promoters and UTRs-or mutation types [20] [21] [22] [23] . These approaches either presume the relevant targets of disruption or disregard the established heterogeneity among cancer types at the level of driver genes and pathways 5, 24, 25 as well as in nucleotide-specific mutation probabilities 3, 4 . Yet, systematic analyses of genomic regulatory activity in animals have identified substantial tissue and developmental stage specificity [26] [27] [28] , suggesting that mutations in cancer type-specific regulatory features may be significant noncoding drivers of cancer.
To address these diverse limitations, we employed density-based clustering techniques using cancer-, mutation type-and genespecific mutation models to identify regions of recurrent mutation in 21 cancer types. This approach permitted the unbiased identification of variably sized genomic regions recurrently altered by somatic mutation, which we term significantly mutated regions (SMRs). We identified SMRs in numerous well-established cancer drivers as well as in new genes and functional elements. Moreover, SMRs were associated with noncoding elements, protein structures, molecular interfaces, and transcriptional and signaling profiles, thereby providing insight into the molecular consequences of accumulating somatic mutations in these regions. Overall, SMRs identified a rich spectrum of coding and noncoding elements recurrently targeted by somatic alterations that complement gene-and pathway-centric analyses. 1 1 8 VOLUME 48 | NUMBER 2 | FEBRUARY 2016 Nature GeNetics a n a ly s i s
RESULTS

Multiscale detection of SMRs
We examined ~3 million previously identified 5 somatic single-nucleotide variants (SNVs) from 4,735 tumors of 21 cancer types, recording 29 their impact on protein-coding sequences, transcripts and adjacent regulatory regions (Supplementary Fig. 1 ). We note that 79.0% (n = 2,431,360) of these somatic mutations do not alter protein-coding sequences or their splicing and thus were not previously considered in the analysis of cancer driver mutations 5 (Fig. 1a) .
To discover both coding and noncoding cancer drivers, we applied an annotation-independent density-based clustering technique 30 to identify 198,247 variably sized clusters of somatic mutations within exonproximal domains of the human genome ( Fig. 1b and Online Methods). We included synonymous mutations because functionally important noncoding features can be embedded within coding regions [13] [14] [15] [16] [17] [18] .
Mutation density scores within each identified cluster were derived as the Fisher's combined P value of the individual binomial probabilities of observing k or more mutations for each mutation type within the region in each cancer type (Online Methods). We evaluated mutation density for each cluster using gene-specific and genome-wide models of mutation probability ( Supplementary Fig. 2) , which were well correlated ( Supplementary Fig. 3a) , selecting the more conservative estimate for each cluster as the final density score (Online Methods). Gene-specific mutation probability models accounted for sequence composition (GC content) as well as differences in local gene expression and replication timing, which have been shown to correlate with somatic mutation rate 4 . To avoid skewed mutation probability estimates due to selection pressure on exons, we applied a Bayesian framework to derive gene-specific mutation probabilities given intronic mutation probabilities in cancer whole-genome sequencing data 3, 20 while controlling for differences in sensitivity in whole-exome and whole-genome sequencing (Online Methods).
Although many known cancer-related genes did not display signals of high mutation density, increasing density scores correlated with stronger enrichments (up to 120×) for somatic SNV-driven cancer genes (n = 158), as determined by the Cancer Gene Census (CGC; Supplementary  Fig. 3b,c) 31, 32 . Moreover, ~10% of genes associated with SMRs in the quintile with the top density scores were not found previously in a genelevel analysis 5 or in the CGC. Thus, high density scores are enriched for known cancer genes but also nominate potentially new drivers.
We applied Monte Carlo simulations to select density score thresholds controlling the false-discovery rate (FDR) to ≤5% ( Supplementary  Fig. 4 and Supplementary Table 1 ). We identified 872 significantly mutated regions (SMRs; Fig. 1c ) that were altered in ≥2% of patients in 20 cancer types for further characterization (Fig. 1d) . SMRs spanned 735 genomic regions, which were assigned unique SMR codes (for example, TP53.1). Note that some SMRs (n = 120) appeared in more than one cancer type. npg a n a ly s i s
We classified SMRs into high-, medium-and low-confidence sets on the basis of their density scores and contribution from mutator samples (Online Methods and Supplementary Table 2 ). We observed correspondingly high (63.3×; P = 2.5 × 10 −46 ), medium (6.2×; P = 2.6 × 10 −10 ) and low (5.0×; P = 5.0 × 10 −4 ) enrichments for somatic SNV-driven cancer genes in these sets. To control for unaccounted processes that could result in clusters of mutations with no selective advantage in cancer, we leveraged single-nucleotide and trinucleotide density scores from intronic mutation clusters under the assumption that these clusters are non-functional (Online Methods). This procedure identified 205 'robust' SMRs that passed a false-discovery threshold (FDR ≤ 5%) in these secondary tests or were found in multiple cancer types. Fully 95.0% of high-confidence SMRs in the cancer types where these tests could be applied satisfied these stringent alternate criteria ( Supplementary Fig. 5 ). Over 87% of SMRs were contained within mappable (100-bp) regions of the genome, and an analysis of 6,179 recently published breakpoints 33 yielded a single SMR (in PTEN) within 50 bp of a resolved breakpoint, suggesting that the observed mutation density in SMRs is not attributable to mapping artifacts.
SMRs display a wide range of sizes ( Fig. 1e ; median = 17 bp, range = 1-2,041 bp), are robust to distinct mutation background models ( Fig. 1f and Online Methods), are not driven by unaccounted mutation contexts ( Supplementary Fig. 6 ), and are enriched in protein-coding, 5′ UTR and splice-site mutations (P < 0.01; Fig. 1g ). Notably, SMRs are not driven by samples that contribute large numbers of mutations per region (Fig. 1h) . This is in contrast to recently proposed regions of recurrent alteration 20 where as few as five regions were driven exclusively by distinct samples (P = 6.0 × 10 −45 , Wilcoxon rank-sum test). Thus, we have identified a diverse set of variably sized SMRs targeted by recurrent somatic alterations, and we sought to characterize their relevance to functional elements and cancer-associated genes.
SMRs enrich for known cancer genes and implicate new ones
SMRs are predicted to have diverse impacts on 610 genes and are 8.35-fold enriched in known genes with somatic cancer-associated alterations (Lawrence et al. 5 or CGC, P = 8.1 × 10 −49 , hypergeometric test), affecting a total of 91 known drivers, including canonical oncogenes (for example, BRAF, KRAS, NRAS, PIK3CA and CTNNB1) and tumor suppressors (for example, PTEN, TP53 and APC). SMRassociated genes also include 17 CGC genes previously undetected in a gene-level analysis 5 , such as established oncogenes like BCL2 and PIM1 and the cancer-associated noncoding gene MALAT1. Most coding SMRs are driven by nonsynonymous mutations ( Supplementary  Fig. 7) , demonstrating that SMRs capture positive selection primarily acting on protein alterations. The presence of SMRs implicates 26 known cancer genes in 31 gene × cancer type associations not uncovered by gene-level analysis 5 ( Supplementary Table 3 ). We note, however, that most known cancer genes do not harbor regions of dense mutation recurrence within these data ( Supplementary Fig. 8 and Supplementary Note), suggesting that SMR identification complements gene-level approaches.
We discovered SMRs in multiple new cancer driver genes, including the breast cancer-associated antigen and putative transcription Erg* FLI1* FEV* NFATC2* ELK4*
3 9 ,6 0 5 ,9 7 0 3 9 ,6 0 5 ,9 6 6 Chr. 7 (+) bp 1 5 5 ,9 0 4 ,2 5 0 1 5 5 ,9 0 4 ,2 5 A npg a n a ly s i s factor ANKRD30A 34 , in which ~21% of melanomas harbored mutations within one or more of three SMRs. Mutations in these SMRs were validated in whole-genome sequencing data for six of 17 cutaneous melanomas 3, 20 . Within the entire gene body, 27 of 118 whole-exome and ten of 17 whole-genome sequencing data sets from patients with melanoma harbored somatic protein-altering mutations in ANKRD30A. Overall, of the 185 high-confidence SMRs, 16 were associated with new cancer driver genes ( Supplementary Table 4 ). As expected on the basis of methodological differences, these putative new cancer drivers are primarily (~81%) driven by noncoding alterations, as discussed in the next section.
SMRs implicate diverse noncoding regulatory features
A significant proportion (31.2%; P < 2.2 × 10 −16 , proportions test) of SMRs are not predicted to affect protein sequences, highlighting the potential to discover pathological noncoding variation in wholeexome sequencing data. In total, 130 SMRs lay within open chromatin 28 and were enriched in promoter (4.9×; q = 4.0 × 10 −9 ) and 5′ UTR (6.0×; q = 4.4 × 10 −10 ) features ( Supplementary Table 5 ). Three promoter SMRs coincided with regions deemed significantly mutated in a pan-cancer analysis of whole-genome sequencing data 20 . Across all cancer types, small (≤25-bp) noncoding SMRs were enriched in binding sequences for ETS oncogene family (7.4×; q = 2.6 × 10 −6 ) and winged-helix repressor (3.2×; q = 2.0 × 10 −4 ) transcription factors ( Fig. 2a and Supplementary Table 6 ). We also detected cancerspecific transcription factor motif enrichments within SMRs from diffuse large B cell lymphoma, melanoma and rhabdosarcoma ( Fig. 2b and Supplementary Table 7) .
We discovered 4-bp and 5-bp SMRs within open chromatin sites of the KIAA0907 and YAE1D1 promoters that were altered in 10.2% and 9.3%, respectively, of melanomas analyzed by whole-exome sequencing ( Fig. 2c,d) . Somatic mutations in these SMRs were confirmed in whole-genome sequencing data for melanomas (n = 1 for KIAA0907 and n = 2 for YAE1D1 of n = 17 cases) 3, 20 . Yet, these regions did not reach significance in a pan-cancer analysis 20 , highlighting cancer specificity in noncoding alterations. In both SMRs, mutations altered core recognition sequences within in vivo ETS factor binding sites (Encyclopedia of DNA Elements (ENCODE)), with varying effects on ETS primary sequence preferences. KIAA0907 encodes a putative RNA-binding protein. However, intronic sequences in this gene harbor SNORA80E (also known as SNORA42), an H/ACA class small nucleolar RNA (snoRNA) with increased expression in lung and colorectal cancers 35, 36 , suggesting that promoter SMR alterations may enhance transcription at this locus. However, we observed no detectable changes in reporter gene expression with the mutant KIAA0907 promoter ( Fig. 2e) . Whereas YAE1D1 promoter mutations reduced reporter gene expression ( Fig. 2e) , RNA-level overexpression of YAE1D1 has previously been observed in lower crypt-like colorectal cancer 37 and a small cohort of melanoma samples showed increased YAE1D1 protein levels in comparison to untransformed melanocytes 38 .
In addition to SMRs that influence promoter regions, we observed 32 SMRs in 5′ and 3′ UTRs, including putative microRNA (miRNA) target sites 39 . Most strikingly, we discovered a 3-bp SMR in the 5′ UTR of TBC1D12 that was mutated in ~15% of bladder cancers (Fig. 2f) . Recurrent mutations were positioned near the start codon (Kozak npg a n a ly s i s region positions −1 and −3), suggesting a role in translational control. Mutations in this SMR were validated in the whole-genome sequences of seven cancer types, including two of 20 bladder cancers, two of 40 lung adenomas and three of 172 breast cancers 3, 20 . Bladder tumors with mutations in this SMR displayed altered RPS6KA1 (p90RSK) phosphorylation (P = 0.0005, t test, Benjamini-Hochberg), a signal of increased cell cycle proliferation 40 , and altered α-tubulin levels (P = 4.3 × 10 −5 , t test, Benjamini-Hochberg), as determined by reversephase protein array (RPPA) assays 41 (Fig. 2g and Online Methods). These results establish the usefulness of whole-exome sequencing data for identifying recurrently mutated noncoding regions and our SMR identification method in pinpointing potentially functional noncoding alterations in cancer.
SMRs permit high-resolution analysis of coding alterations
As expected, most exome-derived SMRs lay within protein-coding regions. The identification of SMRs across multiple cancer types permitted a systematic analysis of differential mutation frequencies with subgenic and cancer type resolution. Although many protein domains showed high burdens of somatic alteration in multiple cancers, protein domains can show remarkable cancer type specificity in burdens of alteration, as exemplified by VHL in kidney clear cell carcinoma and SET in diffuse large B cell lymphoma (Fig. 3a) .
Among genes (n = 94) with multiple SMRs, we detected 48 SMRs that were differentially mutated across cancer types ( Supplementary  Table 8 ). A striking example of this differential targeting occurred within the catalytic subunit of the phosphoinositide 3-kinase subunit PIK3CA (p110α), a key oncoprotein implicated in a range of human cancers 42, 43 . We detected six SMRs in PIK3CA across eight cancer types (Fig. 3b) , with multiple cancer types displaying SMRs mapping to the helical (PIK3CA.5) and kinase (PIK3CA.6) domains. In contrast, we observed cancer type-specific SMRs (PIK3CA.2 and PIK3CA.3) affecting an α-helical region between the adaptor-binding domain (ABD) and the linker region between the ABD and Ras-binding domain (RBD) of PIK3CA. Up to 14% of uterine corpus endometrial carcinomas harbored alterations in these intron-separated SMRs, although these regions were not highly recurrently altered in other cancers. For example, we observed significant (q = 1.2 × 10 −16 , proportions test) differences in PIK3CA.2 alteration frequencies in endometrial and breast cancers (Fig. 3b) and further validated these differences (P = 0.02, proportions test) in whole-genome sequences 3, 20 . These findings indicate that previously described differences 44 in total PIK3CA mutation frequency between endometrial and breast cancers could, in part, be localized to this region.
Although the oncogenic effects of recurrent mutations mapping to the ABD (PIK3CA.1), C2 (PIK3CA.4), helical (PIK3CA.5) and kinase (PIK3CA.6) domains of PIK3CA have been previously described, mutations affecting the ABD-RBD linker region are poorly understood [45] [46] [47] [48] . Interestingly, missense alterations within this region were directionally orientated to one side of the α helix (P = 0.0145, Rayleigh test), suggesting changes to a molecular interface ( Fig. 3c) . Largescale molecular dynamics simulations of PIK3CA-PIK3R1 binding indicate that PIK3CA.2 (p.Lys111Glu) and PIK3CA.3 (p.Gly118Asp) substitutions can alter intermolecular salt-bridge patterns at Arg79, which may result in a loss of 1.8 kcal/mol in binding interactions in comparison to wild-type PIK3CA (Fig. 3d , Online Methods and Supplementary Fig. 9 ). Taken together, these results suggest a previously unrecognized mechanism of oncogenic alteration in PIK3CA.
To systematically characterize the location of alterations with respect to three-dimensional protein structures, we leveraged structural information from 428 SMR-associated and known cancer genes. We detected 46 proteins with three-dimensional clustering of missense alterations (Supplementary Table 9) , as exemplified by PIM1, an SMR-associated serine/threonine kinase proto-oncoprotein ( Fig. 3e and Online Methods). This approach also identified three-dimensional clustering between BRAF V600 and BRAF P-loop SMRs (Fig. 3f) , regions where alterations have been shown to function through distinct mechanisms 49 . Moreover, we found that BRAF V600 alterations were more frequent in melanoma and colorectal cancers, whereas BRAF P-loop alterations were more common in multiple myeloma and lung adenomas (P < 0.01, proportions test). In total, seven of 16 proteins with multiple SMRs displayed significant SMR three-dimensional npg a n a ly s i s clustering ( Supplementary Table 10 ), which is consistent with frequent spatial coherence for pathogenic alterations. We next sought to identify SMRs that might affect the molecular interfaces of protein-protein and DNA-protein interactions, a recognized yet understudied mechanism of cancer driver mutation [50] [51] [52] . We examined intermolecular distances between SMR residues and interacting proteins or DNA and identified 17 SMRs that likely alter molecular interfaces ( Table 1 and Online Methods). These included 15 molecular interfaces of protein-protein and DNA-protein interactions with established cancer associations, such as the substrate-binding cleft of SPOP 53 and DNA-binding interfaces on RUNX1 (Fig. 3g) . We detected reciprocal SMRs at all electrostatic interfaces of the SMAD2-SMAD4 heterotrimer in colorectal cancer (Fig. 3h) , as have been recently described 54 , and reciprocal SMRs at the regulatory PIK3CA-PIK3R1 interface in endometrial cancer (Fig. 3b) . Taken together, these results highlight the robustness of SMRs in detecting validated driver alterations at molecular interfaces (Supplementary Fig. 10 ). In addition, SMRs pinpoint recurrent alterations at the interface between histone H3.1 (Fig. 3i) and TRIM33, an E3 ubiquitin ligase, and at the DNA-protein interface of histone H2B (Supplementary Fig. 11 ). These findings underscore and extend recent associations between altered epigenetic regulation and histone alterations in tumorigenesis 55 .
Molecular signatures highlight impact of SMR alterations
We sought to determine the potential functional impact of SMR alterations by their association with molecular signatures. We leveraged RNA sequencing (RNA-seq), RPPA and clinical data to ask whether (i) SMR alterations associate with distinct molecular signatures or survival outcomes, (ii) SMR alterations correlate with similar molecular profiles in distinct cancers, and (iii) SMR alterations in the same gene associate with similar or different molecular signatures.
We found that mutations in SMRs were associated with diverse changes in RNA expression, signaling pathways and patient survival ( Fig. 4a , Online Methods and Supplementary Tables 11-14) 56 . These analyses identified previously unappreciated connections between recurrent somatic mutations and molecular signatures, which highlight recurrent GSK3 pathway alterations in endometrial cancer and recurrent mTOR as well as EIF4 and epidermal growth factor (EGF) pathway alterations in glioblastoma ( Supplementary Table 15 ). For example, synonymous point mutations in a bladder cancer SMR in SNX19 (encoding sorting nexin 19) were associated with significant increases in the protein expression levels of RAB25 (P = 2.5 × 10 −27 , t test; Fig. 4b and Supplementary Table 12 ), a RAS family GTPase that promotes ovarian and breast cancer progression 57, 58 . These increases are consistent with RNA expression differences in RAB25 (P = 0.02, Wilcoxon rank-sum test; Fig. 4c ). Intriguingly, both SNX19 and RAB25 are implicated in intracellular trafficking, but the mechanism by which synonymous mutations in SNX19 correlate with RAB25 expression remains to be determined. In both SNX19 and NDUFA13, SMRs with clusters of synonymous mutation overlapped open chromatin sites 28 , suggesting potential regulatory effects.
We identified concordant changes in gene expression for SMR pairs, suggesting potential functional relationships, for 23 SMRs from 17 genes (Fig. 4d) . These included multiple well-established mechanistic relationships, many of which were supported by RPPA measurements 41 , such as a relationship between PIK3CA and AKT1. Furthermore, this analysis indicated that mutations in the same SMR in different cancers can elicit similar molecular profiles in distinct cancers. For instance, Fig. 4e) .
The four genes with the highest increases in gene expression among endometrial cancer samples with alterations in NFE2L2.1 were the aldo-keto reductases AKR1C1-AKR1C4 (Fig. 4e) , which contribute to altered androgen metabolism and have been implicated in multiple cancer types [60] [61] [62] . Across all four cancer types, genes with expression changes in patients with mutations in NFE2L2 SMRs were highly enriched for oxidoreductases acting on the CH-OH group of donors with NAD + or NADP as acceptors (4.9-39.0×; P ≤ 0.001, Benjamini-Hochberg; Fig. 4f ). Mutations in KEAP1, encoding an NFE2L2 binding partner, recapitulated the expression changes observed in patients with mutations in NFE2L2 SMRs (P < 0.01, Benjamini-Hochberg; Fig. 4g and Supplementary Fig. 12) .
The identified SMRs also permitted interrogation of mutations in different regions of a given gene with respect to associated molecular signatures. For example, in breast cancer, alterations in distinct SMRs within TP53 were associated with highly similar changes in protein levels. Yet, we observed SMR-specific differences in ASNS levels and MAPK and MEK1 phosphorylation among samples with altered TP53 SMRs (q < 0.01; Fig. 4h ). These results establish differences in the molecular signatures associated with alterations of SMRs in the same gene and are consistent with pleiotropy in established oncogenes and tumor suppressors 63, 64 .
The structure of cancer mutations remains largely unseen SMR analysis leverages structure in the distribution of somatic driver mutations to identify cancer-associated regions. We sought an alternative metric to assess structure in the distribution of the somatic coding mutations analyzed here by measuring the Gini coefficient of amino acid substitutions per residue in each cancer type (Fig. 5a) . Gini coefficients of dispersion were well correlated with sample numbers (Spearman's ρ = 0.74). Subsampling demonstrated that, even with sample numbers >850, a large proportion of the structure of protein-altering mutations in breast cancer remains unseen (Fig. 5b) . These findings highlight the value of increasing cancer sample sizes in assessing the landscape of driver mutations.
DISCUSSION
With few exceptions, studies of disease-associated variation have focused on identifying predefined functional units with recurrent alterations. This approach not only assumes accurate annotations but ignores the largely uncharacterized spectrum of functional elements that may be the targets of pathological variants. Our approach avoids these limitations and complements existing gene-level and pathwaybased strategies for discovering cancer drivers by identifying variably sized SMRs ( Supplementary Table 16 ). SMR-associated genes include known cancer-related genes, such as PIM1 and MIR142, that were missed by gene-level analyses, as well as multiple genes with potentially novel roles in cancer development.
Cancer-associated SMRs target a diverse spectrum of functional elements in the genome, including single amino acids, complete coding exons and protein domains, miRNAs, 5′ UTRs, splice sites and transcription factor binding sites, among others. This functional diversity underscores both the varied mechanisms of oncogenic misregulation and the advantage of functionally agnostic detection approaches. Notably, several of the most frequently altered SMRs lay within noncoding regions. Strikingly, 17 of 39 promoter and 5′ UTR melanoma SMRs overlap the core recognition sequences of in vivo ETS family binding sites (odds ratio = 15.2, P = 1.5 × 10 −11 , Fisher's exact test). In addition, ~15% of patients with bladder cancer harbor 5′ UTR alterations in TBC1D12. Together, these results extend the support for noncoding drivers in cancer 20, 23, 65 and establish the potential for discovering noncoding variation in whole-exome sequencing.
The identification of SMRs provides a subgenic, cancer typespecific analysis of somatic mutations and associated molecular signatures. Differences among cancer types in SMR mutation frequencies within BRAF, EGFR and a mechanistically uncharacterized α helix in PIK3CA demonstrate substructure in the distribution of somatic mutations across cancers, a property that may arise from pleiotropic functions. The close geometric proximity and directional uniformity of alterations in the PIK3CA helix suggest that mutations in the PIK3CA.2 and PIK3CA.3 SMRs function through similar mechanisms. Moreover, biophysical simulations indicate that mutations in both SMRs result in elevated basal signaling activity of catalytic PIK3CA by way of weakened interactions with the regulatory PIK3R1 protein.
These findings are concordant with recent biochemical evidence 48 . Consistent with pleiotropic dependencies, alterations to SMRs within a single gene can be associated with distinct molecular signatures, as exemplified by TP53 SMRs in breast cancers. Together, these results provide robust support for subgenic functional targeting in distinct cancers and genes, and future efforts to examine SMR mutations in conjunction with clinical data in much larger patient cohorts may permit assessment of the prognostic value of SMRs.
SMR detection would benefit from further improvements of somatic mutation models. Here we have applied cancer type-specific models that take into account variation in somatic mutation rates throughout the genome. We controlled for mutational effects stemming from npg a n a ly s i s differences in replication timing and gene expression 4, 66 . In addition, our models capture nucleotide-specific mutation probabilities 3 , account for strand specificity 67 , leverage whole-genome sequencing mutation frequencies to limit effects from purifying selection on exons and control mutation processes that may result in mutation clustering and trinucleotide mutation biases 3 . However, tumor-specific DNA repair defects 3, 66, 68, 69 and cell type-specific chromatin context 70 also contribute to somatic mutation rates. Mutation models that account for cell type-specific expression and chromatin context at refined scales may require sequencing cohorts of matched normal tissue and increased sample sizes.
Although the sequencing of additional cancer genomes will likely further the identification of new cancer driver genes 5 , characterizing the biochemical and cellular consequences of individual mutations is critical. We demonstrate that identifying the spatial distribution of mutation recurrence in the genome, when combined with additional genomic, biophysical, structural or phenotypic information, often enhances mechanistic insights. Applying recently developed high-throughput approaches [71] [72] [73] to directly interrogate variation within SMRs may allow further understanding of the molecular mechanisms driving cancer and facilitate diagnostics and therapeutics development.
URLs. Data from Lawrence et al. 5 were obtained from TumorPortal through http://www.tumorportal.org/. TCGA Data Portal, https:// tcga-data.nci.nih.gov/tcga; UCSC Cancer Browser, http://genome-cancer. ucsc.edu/.
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Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINE METhODS
Scientific computing was performed within Python 74, 75 and R environments. Data structure and genomic interval operations were performed with PANDAS 76 and Pybedtools 77 , respectively. Statistical computing was performed with SciPy and NumPy 78 , and machine learning methods were implemented with SciKit Learn 79 . Structural and sequence alignment analyses were performed with BioPython 80 , PyMOL (Schrödinger) modules and custom scripts. RPPA, RNA-seq and survival analyses were performed in R using open source packages (as described below).
Uniform variant annotation. 3,185,590 uniformly processed 5 whole-exome sequencing somatic variant calls from 21 cancer types were downloaded from the indicated URL. We applied snpEff 29 to uniformly annotate n = 3,078,482 (96.6%) SNV calls from 4,735 tumors, recording (GRCh37.66) mutation impact in protein-coding regions, transcribed regions (coding plus noncoding exons, introns, 5′ UTRs and 3′ UTRs) and gene-associated regions (transcribed 5 kb upstream and 5 kb downstream) and standardize gene name assignments. These procedures standardized gene name assignments at multiple scales and removed gene assignments to "?" (n = 64) and "-" (n = 130,728) in the original file. In addition, this procedure reduced variant calls unassigned to any genes ("Unknown", n = 1,239,475) to n = 899,731 intergenic calls (>5 kb from annotated exons). This procedure was also applied to annotate n = 11,461,951 whole-genome sequencing somatic SNV calls from 23 cancer types 3, 20 .
Mutation probability models. For each tumor type and gene, we calculated multiple distinct mutation probabilities. First, we calculated the frequency of transitions and transversions within the mappable, exonic regions of each gene to derive 'exonic' mutation probabilities for each gene in the hg19 human genome assembly using whole-exome sequencing data. Specifically, these probabilities indicate the fraction of mappable (100-bp), exonic reference bases (for example, adenines) in each gene that were somatically mutated to a specific base (for example, cytosine) per sample, in the cohort of tumorspecific whole-exome sequencing data.
Because expression levels and replication timing have been shown to be major covariates of somatic mutation probability in the genome, we sought to refine our mutation probability models for each gene using this information. For each gene and in each tumor type, we identified the set of genes most similar in expression, replication time and GC content (gene-level features). We used previously compiled 4 expression and replication timing data and derived feature-specific weights defined as the rank correlation between gene features and the observed exonic mutation probabilities in each tumor type. We then converted gene features into their percentile ranks. Genes were sorted sequentially on the basis of the gene feature weights, and the neighborhood of the 500 closest genes was selected for each query gene. We then measured the sum of correlation-weighted, absolute feature distances between gene pairs within the 500-gene rank neighborhood. For each gene, we selected the ≤200 most similar genes with a normalized distance score ≤1. Lastly, we averaged the 'exonic' mutation probability per transition/transversion to derive a set of 'matched' mutation probabilities.
To avoid skewed mutation probabilities due to increased selection pressure on exons, we used pan-cancer whole-genome sequencing 3,20 data in conjunction with cancer-specific whole-exome sequencing data. We employed a Bayesian framework to derive posterior mutation probabilities for each transition and transversion per gene in each of the analyzed cancer types. Specifically, we modeled the likelihood of observing a mutation as a binomial distribution. We placed a prior beta distribution on the mutation probability for each mutation type. The prior distribution was parameterized with parameters α = µ × ν and β = (1 − µ) × ν, where µ is the per-base mutation probability in the whole-exome sequencing data and ν is the number of exome sequencing samples in each cancer type. This parameterization enables the variance of the prior distribution to scale inversely with sample size. We used the set of genes (≤200) that were matched to the analyzed gene as described above. We used all observed intronic whole-genome sequencing mutations in this cancer-specific matched set to calculate the posterior mutation probability for the analyzed gene. In this framework, the posterior distribution is also another beta distribution. We then assigned the expected value of the posterior probability distribution as the estimate of the mutation probability for each transition/transversion (n = 12). Finally, we calibrated the posterior mutation probabilities by the cancer-specific transition/transversion rates such that the median 'Bayesian' mutation probability was equal to the mean cancer-specific 'exonic' mutation rate.
We computed a 'global' mutation probability per tumor type as the average probability of transitions and transversions across all genes as observed in 'exonic' mutation probabilities in each tumor type. The distributions of whole-exome sequencing-derived ('exonic' , 'matched' and 'global') as well as whole-genome sequencing-derived ('Bayesian') mutation probabilities varied strongly between cancer types (Supplementary Fig. 2a ) and among genes within individual cancer types, highlighting the importance of such cancer-and gene-specific treatment of background mutation probabilities 3, 4 . Complementary mutation probabilities were well correlated ( Supplementary  Fig. 2b) . The 'Bayesian' and 'matched' mutation probabilities were well correlated among genes (Supplementary Fig. 2c) , although 'Bayesian' mutation probabilities were better correlated (Supplementary Fig. 2d ) with the observed whole-genome sequencing intronic mutation densities. These 'Bayesian' (whole-genome sequencing-based) and 'matched' (whole-exome sequencing-based) mutation probabilities were used for the comparison presented in Figure 1f .
Lastly, to account for trinucleotide biases 3, 4 in diverse mutation processes and cancer types, we computed 'trinucleotide' mutation probability models for each tumor type. Specifically, 'trinucleotide' mutation probabilities were calculated as the fraction of mappable (100-bp), exonic reference bases (for example, adenines) within specific trinucleotide contexts (for example, CAG) that were somatically mutated to a specific base (for example, cytosine, CAG>CCG) per sample, in the cohort of tumor-specific whole-exome sequencing data.
Mutation domain definition. We extended Ensembl (75) exonic regions by 0 bp and 1,000 bp and merged regions to define n = 305,145 'concise' (C) and n = 191,669 'expanded' (E) genomic domains in which mutation clusters were evaluated (see below). We identified the n = 279,979 'concise' and n = 175,228 'expanded' domains in which over ≥90% of positions were fully mappable with single-end 100-bp reads (ENCODE, UCSC Genome Browser). For each set of domains, we computed the number of possible genomic ranges (start, stop), which for the 'expanded' set amounted to 1,005,774,400,023 ranges (10 12.0025 ). In addition, we removed 'blacklisted' regions of the human genome previously defined by the ENCODE Project 81 .
Mutator sample identification. Samples harboring aberrantly high burdens of mutations in each tumor type were detected using median absolute deviation (MAD) outlier detection on the distribution of mutations (log n) per sample. As a threshold for consistency, mutator (outlier) samples were selected as those exceeding 2 s.d.
Mutation cluster identification.
We deployed density-based spatial clustering of applications with noise (DBSCAN) to detect clusters of ≥2 SNVs within exonic domains (above), evaluating density reachability within ε base pairs in each cancer type. The reachability parameter ε was dynamically defined with ε = d p /d s where d p and d s refer to the number of mutated positions (base pairs) and the base-pair size of the domain d, thresholded to 10 ≤ ε ≤ 500 bp. In contrast to sliding window approaches or k-means spatial clustering, DBSCAN is not confined to evaluating predefined cluster sizes or numbers and tolerates noise in spatial density, whereby distal mutations are not assigned to clusters. Detected mutation clusters were refined where subclusters of ≥2 SNVs with significantly higher (P < 0.05, binomial test) mutation densities (mutated tumor samples per kilobase) existed.
Mutation cluster scoring. The significance of the observed mutation densities in each cluster was determined as Fisher's combined binomial probability of sampling the observed number (k) or more mutations for each mutation type within the region. For each region, we computed the above density scores with the previously described 'exonic' , 'matched' , 'Bayesian' and 'global' somatic mutation probabilities. As the primary density score (P density ), we selected the most conservative of the 'Bayesian' and 'global' density scores, max(P Bayesian , P global ). 
